NCT07070999View on ClinicalTrials.gov

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

April 30, 2029

Conditions
Spinal Muscular Atrophy Type I
Interventions
BIOLOGICAL

GB221

GB221

Sponsors
All Listed Sponsors
lead

Gemma Biotherapeutics

INDUSTRY

NCT07070999 - Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1 | Biotech Hunter | Biotech Hunter